3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Hepatocellular
9
Neoplasms
4
Melanoma
4
Breast Neoplasms
4
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Sarcoma
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Polycystic Ovary Syndrome
2
Pleural Effusion, Malignant
2
Neoplasm Metastasis
2
Mesothelioma, Malignant
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Head and Neck Neoplasms
2
Anxiety Disorders
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Recurrence
1
Rare Malignant Neoplasm
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
NSCLC
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphedema
1
Locally Advanced Bladder Cancer
1
Immunoglobulin Light-chain Amyloidosis
1
Interventions
Cisplatin
7
Etoposide
6
Amifostine
6
Radiotherapy
5
Drug Therapy
5
Cyclophosphamide
5
apatinib
4
Methotrexate
4
Filgrastim
4
Cytarabine
4
sodium thiosulfate
3
Methylprednisolone
3
Carboplatin
3
pegfilgrastim
2
glucarpidase
2
etoposide phosphate
2
Voriconazole
2
Vincristine
2
Social Determinants of Health
2
Pyridoxine
2
Nivolumab
2
Gemcitabine
2
Doxorubicin
2
Docetaxel
2
Chemotherapy, Adjuvant
2
Capecitabine
2
trastuzumab deruxtecan
1
selinexor
1
sargramostim
1
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Drug-Related Side Effects and Adverse Reactions
×
Pharmaceutical Preparations
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled